Are you Dr. Shepard?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 88 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
4220 Harding Pike
SE Building Suite 200
Nashville, TN 37205Phone+1 615-385-3751Fax+1 615-269-7085
Summary
- Dr. Gregg Shepard, MD is an oncologist in Nashville, Tennessee. He is currently licensed to practice medicine in Tennessee and North Carolina. He is affiliated with Ascension Saint Thomas and Ascension Saint Thomas.
Education & Training
Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008- Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 2002 - 2005
University of Tennessee Health Science Center College of MedicineClass of 2002
Certifications & Licensure
TN State Medical License 2008 - 2026
NC State Medical License 2002 - 2009- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- National Board of Physicians and Surgeons Hematology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Publications & Presentations
PubMed
- 11 citationsA Phase II Study with Lead‐In Safety Cohort of 5‐Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients w...Gregg C. Shepard, Edward Arrowsmith, Patrick Murphy, J. H. Barton, James D. Peyton
The Oncologist. 2017-10-01 - 88 citationsA phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningiomaKent C. Shih, Sajeel Chowdhary, Paul Rosenblatt, Alva B. Weir, Gregg C. Shepard
Journal of Neuro-Oncology. 2016-06-16 - 65 citationsPhase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.John D. Hainsworth, Kent C. Shih, Gregg C. Shepard, Guy W Tillinghast, Brett T Brinker
Clinical Advances in Hematology & Oncology. 2012-04-01
Professional Memberships
- Member
